Once-monthly efimosfermin alfa prescribed for metabolic dysfunction–associated steatohepatitis with F2 and F3 fibrosis ...

Naim Alkhouri, MD, spoke to the potential for glucagon-like peptide-1 (GLP-1) receptor agonists to transform the treatment landscape for patients with metabolic dysfunction-associated steatohepatitis ...

Target RWE, a leader in modern clinical evidence generation for complex diseases, today announced its presentations and strategic contributions at the EASL Congress 2025 in Amsterdam, Netherlands.

AMSTERDAM — A once daily, 50 mg dose of efruxifermin reduced fibrosis at 96 weeks in patients with compensated cirrhosis due to metabolic dysfunction-associated steatohepatitis (MASH) compared with ...

Source: Malaria cases in Mash West increase – herald Conrad Mupesa-Mashonaland West Bureau MASHONALAND West Province is ...

The publication reports results from the 96-week SYMMETRY study evaluating the efficacy and safety of Akero's lead FGF21 ...

A CAMPAIGNING MP stepped in the ring with an unbeaten professional boxer in his fight to protect pie and mash. Talented welterweight Finley James lent his full support to Richard Holden’s campaign to ...

With a quick scan of Factor's website and menu, it is quite clear the company is targeting the health, fitness and diet crowds. You will find lots of lean proteins like chicken and salmon along with ...

“It is an absolute phenom for us to be able to present to you now our teenage aspirations in this song”: Joe Satriani and ...

Gyre Therapeutics ("Gyre”) (Nasdaq: GYRE), an innovative, commercial-stage biotechnology company focused on organ fibrosis, today announced financial results for the first quarter ended March 31, 2025 ...

Current No. 3 prospect Bryce Rainer is playing his first professional baseball season after being selected No. 11 overall in the 2024 MLB draft. It has become apparent quickly that teams who passed on ...

Making crispy fries at home can be quite an effort. Meanwhile, delicious potato balls always turn out soft on the inside and ...